IP Library Granted Patent US 8,383,672
Granted Patent B2
US 8,383,672 · App. 13/157,105 · Granted Feb 26, 2013

Halogenated rhodamine derivatives and applications thereof

Inventors: Abdelkrim Habi (Pierrefonds, CA); Denis Gravel (Saint-Lambert, CA); Luc Villeneuve (Montreal, CA); Hongsheng Su (Beaconsfield, CA); Marc Vaillancourt (Chateauguay, CA)
Assignee: Kiadis Pharma Canada Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,672
App. No.
13/157,105
Granted
Feb 26, 2013
Kind
B2
Abstract

Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′,5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide.

Claims (26)

1. A method for treating a tissue sample from a patient, comprising the steps of:

harvesting the tissue sample from the patient, wherein the tissue sample is infected with bacteria;

providing a rhodamine compound, wherein the rhodamine compound is 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester;

mixing the rhodamine compound and the tissue sample to form a mixture,

exposing the mixture to radiant energy to inhibit or kill the bacteria; and

transplanting the exposed mixture into the patient.

2. The method of claim 1 , wherein the bacteria is gram positive.

3. The method of claim 1 , wherein the bacteria is gram negative.

4. The method of claim 1 , wherein the bacteria is Staphylococcus epidermitis.

5. The method of claim 1 , wherein the bacteria is at least one of Escherichia coli 0157:H7 or Salmonella thyphimurium.

6. The method of claim 1 , wherein the mixture is exposed to a wavelength of 514 nm.

7. The method of claim 1 , wherein the tissue sample is blood.

8. The method of claim 1 , wherein the tissue sample is bone marrow.

9. The method of claim 1 , wherein the mixture is exposed to radiant energy for 180 minutes.

10. The method of claim 1 , further comprising the steps of

centrifuging the mixture:

resuspending the centrifuged mixture; and

incubating the resuspended centrifuged mixture.

11. The method of claim 10 , wherein the resuspended centrifuged mixture is incubated for 90 minutes.

12. The method of claim 10 , wherein the resuspended centrifuged mixture is incubated before exposing the mixture to radiant energy.

13. A method for treating a blood sample from a patient, comprising the steps of:

harvesting the tissue sample from the patient, wherein the tissue sample is infected with gram-positive bacteria;

providing a rhodamine compound, wherein the rhodamine compound is 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester;

mixing the rhodamine compound and the tissue sample to form a mixture,

exposing the mixture to radiant energy to inhibit or kill the bacteria; and

transplanting the exposed mixture into the patient.

Assignments (5)
MERGER Recorded Jun 16, 2011
From: CELMED BIOSCIENCES INC.; 9175-9399 QUEBEC INC.
To: KIADIS PHARMA CANADA INC.
Reel/Frame 026468/0198 →
CHANGE OF NAME Recorded Jun 14, 2011
From: CELMED BIOSCIENCES INC.
To: KIADIS PHARMA CANADA INC.
Reel/Frame 026441/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2011
From: HABI, ABDELKRIM; GRAVEL, DENIS; VELLENEUVE, LUC; FORTE, JEAN-PIERRE; SU, HONGSHENG; VAILLANCOURT, MARC
To: THERATECHNOLOGIES, INC.
Reel/Frame 026425/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2011
From: THERATECHNOLOGIES, INC.
To: CELMED BIOSCIENCES INC.
Reel/Frame 026425/0874 →
CHANGE OF NAME Recorded Jun 10, 2011
From: CELMED BIOSCIENCES INC.
To: KIADIS PHARMA CANADA INC.
Reel/Frame 026425/0964 →
Priority Claims (1)
CA 2342675 · Apr 2, 2001 · national
Continuity (4)
Continuation 12786280 · May 24, 2010
Continuation 12403819 · Mar 13, 2009
Division 10297088
Related Publication 20110301573A1 · Dec 8, 2011